Researchers found Novo Nordisk's Ozempic could be manufactured for an estimated 89 cents to $4.73 for a month's supply, figures that include a profit margin.
Given the pharmaceutical industry's assured success driven by innovation and the development of medications targeting diverse healthcare issues, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have
The world is hooked on weight loss drugs and so is the pharmaceutical industry, but as Big Pharma's biggest players and upstart biotechs rush to join the booming market, experts tell Forbes the domina
As we approach the end of the year's first quarter, the stock market has enjoyed a strong run. Three months into 2024 and the benchmark S&P 500 index is already up 10%.
Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals for 1.025 billion euros to establish a presence in cardiovascular disease.

Wall Street Awaits Consumer Confidence Data

11:26am, Tuesday, 26'th Mar 2024
U.S. stock markets saw a pullback on Monday to start a holiday-shortened week. However, Wall Street is likely to record the fifth consecutive winning month despite volatility.
Eli Lilly has a big winner with Zepbound plus other growth drivers and a promising late-stage pipeline. Novo Nordisk's Ozempic and Wegovy are huge successes with more great drugs potentially on the wa
Wall Street is likely to record the fifth consecutive winning month despite volatility.
Novo Nordisk (NVO) closed the most recent trading day at $129.05, moving +0.23% from the previous trading session.
Novo Nordisk AS (NVO), maker of the weight-loss drug Wegovy, is set to acquire Cardior Pharmaceuticals, a German drug company, in a deal for up to 1.025 billion euros ($1.11 billion).
Novo Nordisk is one of the leading drugmakers in the world, developing hit medications such as Ozempic. The company is using artificial intelligence (AI) to process larger volumes of data from clinica
Terry Smith's Fundsmith Equity, the UK's most popular fund, has been downgraded by Morningstar due to questions over the manager's recent portfolio moves.  Fresh from the fund having underperformed
Novo Nordisk, the Danish pharmaceutical whose market cap has swelled due to popular weight loss drugs, on Monday announced it was making an acquisition targeting cardiovascular disease.
Demand for obesity and diabetes treatments such as Ozempic, Mounjaro, and Wegovy is off the charts. Novo Nordisk and Eli Lilly manufacture the primary medications used to treat obesity care and diabet
Denmark's Novo Nordisk on Monday said it has agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros ($1.11 billion) to strengthen its cardiovascular pipeline.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE